We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Not the most positive of updates. Hopefully the market won’t pan it today
Further to my post yesterday and having spoken with IHC the reason for the confusion was due to having a new high tech phone system being installed at the time of my call and the receptionist also being new to the position.
The receptionist was very polite and helpful and having spoken with a member of the sales team today I feel very confident that IHC are experts in their field and will deliver great results for Genedrive.
I just rang to see if I could speak to someone about the Genedrive MT-RNR1 kit and I wasn't that impressed tbh.
Seemed very chaotic and unsure of what I was talking about.
The Genedrive MT-RNR1 kit is advertised on the IHC website so I had expected the receptionist to know what it was.
Perhaps I caught them at a bad time but I hope for GDR's sake these guys are capable of delivering results.
Simon still positive.
https://www.investorschronicle.co.uk/ideas/2022/10/04/a-medtech-winner-in-neonatal-intensive-care/
GLA
Announcement includes the 2nd mention of £0.6m Japanese order for delivery this financial year yet 1st mention of two rather larger orders (each around £1.3m) to Iraq & Egypt respectively. Are those to be delivered in 2nd half of this year or were they delivered in whole or part the 1st half ?
Yes not what we wanted to SEE!
But have modern new production facilties and stock
Poor HI results. Revenue slightly down at £20.5m (LY HI 20.9m) but margins lower at 45.1% (LY 52.5%), Operating profit £1.1m (LY £2.6m) and cash at £3.3m (LY £8.6m). Cash down due to expansion costs and building inventory for H2.
Had been a fan and holder here for several years but sold this morning, before share price collapsed 15%.
May come good in H2, but too many risks with wider economy at present.
RNS wasn't as bad as the market has reacted.... actually fairly positive based on the current economic situation. Still in profit and paying a dividend.
Anyone have an idea as to where the bottom is here?
Down 10% in one day for no apparent reason, until the MMs dropped in a large sell (272k at 82p from around lunchtime) later in the day. Whoever did this must be desperate for cash. Share was around 95-98p prior to sell.
Anyone sensible would have sold in blocks and got a decent price.
Still happy to take advantage and have added more at 85.5p
IHC at Mello2022 investor days on 25/26th May - actively presenting both days and around for chats to investors
The Hyland news article states that revenue might drop by 15% next year. The RNS states that modelling of a 15% drop has been undertaken to verify that borrowing facilities are adequate. The two things are very different. Perhaps the drop in share price today reflects the news article rather than the RNS.
IHC and GDR. Everyones a winner!
Looks like more buying on the strength of the article now that it has hit the paper version released over the weekend.
GLA
Thanks for the link - I expected ST to tip IHC again for good reason - Recent results were excellent and share price had fallen back 30% on general market malaise (tech stocks USA overrated, inflation, Ukraine etc) so offers rich picking for most private investors. I've picked up some more this morning. Bargain at these levels compared to year high 150p.
After market close.
https://www.investorschronicle.co.uk/ideas/2022/02/22/hunting-down-lowly-rated-tech-plays/
GLA
Agreed - you can buy at 105p, that 30% lower than year high price of 150p.
Revenue up 10.9% v a very strong 2020 when one off ventillators were included in the figures.
On top of that, RNS earlier this week that IHC picked up a £1.0m contract wind from Egypt at start of FY2022.
Good news all round and this is real hidden gem.
Share price will take off when the herd get told its a good company and cheap at current price.
In the meantime, fill yer boots!
blimey,looks cheap aswell,on the 3 month
https://www.proactiveinvestors.co.uk/companies/news/974366/inspiration-healthcare-surges-after-raising-guidance-974366.html
Despite the prior year having a one-off rise of £7.3mn, due to covid related revenue, this year they really knocked the ball out of the park.
Excellent performance by the company.
Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that, following the close of the financial year, the Group is expecting to exceed market expectations and to report Group revenues for the financial year ended 31 January 2022 of approximately £41.0 million representing an increase of 10.9% compared to the prior financial year. Adjusted EBITDA* is expected to be not less than £6.2 million, representing growth of 10.5% over the prior financial year, which includes a one-off receipt of £0.2 million. Operating profit is similarly ahead of market expectations.
Cont'd
Simon T
13/10/21
True, annual cash profits are expected to be flat at £5.6m on revenue of £40.6m year on year, but the prior year’s result included £7.3m of one-off Covid-19 related ventilator orders. Strip these out, and house broker Cenkos Securities pencils in 7 per cent revenue growth in the second half, a healthy underlying trend that is not yet fully priced in an enterprise valuation of £75m, or 13.4 times cash profits, after factoring in net cash of £8.6m (12.6p a share). That’s a hefty ratings discount to neonatal medtech peers, Natus Medical (41 times) and Fisher & Paykel Healthcare (23 times).
Simon T
13/10/21
First-half adjusted operating profit up 22 per cent to £2.6m on 47 per cent higher revenue of £20.9m
Analysts upgrade full-year operating profit forecasts by 12 per cent to £3.5m
Integration of SLE acquisition almost complete
Crawley-based Inspiration Healthcare (IHC:123p), a fully integrated medical technology company with a strong focus on the high-growth neonatal intensive care market, has prompted analysts to upgrade their earnings estimates yet again. Last summer’s acquisition of SLE, a designer and maker of ventilators for neonatal intensive care, has been the driver.
That’s because SLE has not only enlarged the group’s global distribution network – 90 per cent of SLE’s sales are export orders with a strong focus on China, Japan, India and the Middle East – but is creating cross-selling opportunities, too. For example, by bundling consumable breathing circuits with the sale of SLE’s ventilators, and expanding market penetration into a larger installed ventilator and consumable customer base, Inspiration can introduce its breathing circuits to new customers who have been using rival products. In the six months to 31 July 2021, the group won an order worth £350,000 for its own brand Viomedex circuits from an SLE distributor in the Middle East.
Inspiration also received regulatory approval in Japan and China for its enhanced top-of-the-range SLE6000 neonatal ventilator that includes features such as enhanced High Frequency Oscillatory Ventilation (designed for use with critically ill infants) and the OxyGenie ® patented oxygen control algorithm (helps maintain infants at their targeted oxygen saturation levels). This led to a significant number of new orders in both countries, and has raised the profile of the group’s neonatal ventilator portfolio internationally.
In the UK, Inspiration’s AlphaCore patient warming system is proving very popular – sales more than doubled year on year – for the prevention of inadvertent hypothermia in neonatal, paediatric and perioperative environments. The benefits of warming are undeniable, such as improved morbidity and mortality, lower infection rates, reduced blood loss and less time in recovery.
The greater focus on higher-margin branded products – 55 per cent of the sales mix, up from 20 per cent in the first half of 2020 – is helping to drive up gross margin (from 41.4 per cent to 52.5 per cent) despite input cost pressures, which are being managed well. The combination of strong organic growth, a robust order book and increased demand across the entire group led to 12 per cent operating profit upgrades for the full year.